Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EPRX Eupraxia Pharmaceuticals	$5.30 -1.8%	$4.79	$2.20 ▼ $6.20	$194.18M	1.51	11,620 shs	4,758 shs
GHRS GH Research	$13.74 -4.3%	$13.82	$6.00 ▼ $20.50	$747.12M	0.97	350,928 shs	273,409 shs
NAGE Niagen Bioscience	$9.04 -3.3%	$11.88	$2.53 ▼ $14.69	$736.50M	2.13	1.10 million shs	1.08 million shs
VIR Vir Biotechnology	$5.03 -0.8%	$5.30	$4.32 ▼ $14.45	$700.87M	1.18	1.08 million shs	809,884 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EPRX Eupraxia Pharmaceuticals	-1.78%	-3.39%	-3.03%	+32.43%	+86.76%
GHRS GH Research	-4.32%	-5.24%	-8.58%	+20.63%	+10.81%
NAGE Niagen Bioscience	-3.32%	-3.00%	-28.14%	+13.00%	+194.46%
VIR Vir Biotechnology	-0.79%	-10.97%	-7.37%	-18.34%	-50.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EPRX Eupraxia Pharmaceuticals	2.5434 of 5 stars	3.6	2.0	2.6	0.0	0.6
GHRS GH Research	2.2656 of 5 stars	3.5	2.0	2.4	2.5	0.0
NAGE Niagen Bioscience	1.0385 of 5 stars	3.5	0.0	0.6	0.0	0.0
VIR Vir Biotechnology	2.8932 of 5 stars	3.4	1.0	2.5	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EPRX Eupraxia Pharmaceuticals	3.17	Buy	$11.00	107.39% Upside
GHRS GH Research	3.00	Buy	$32.00	132.90% Upside
NAGE Niagen Bioscience	3.00	Buy	$13.22	46.24% Upside
VIR Vir Biotechnology	2.88	Moderate Buy	$30.25	501.39% Upside

Current Analyst Ratings Breakdown

Latest EPRX, NAGE, GHRS, and VIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/24/2025	EPRX Eupraxia Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$11.00
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy	$12.00
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/24/2025	GHRS GH Research	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$39.00
6/16/2025	EPRX Eupraxia Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Speculative Buy
6/10/2025	NAGE Niagen Bioscience	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $16.00
6/6/2025	NAGE Niagen Bioscience	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $23.00
6/4/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
5/27/2025	NAGE Niagen Bioscience	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$13.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	$3.44 per share	N/A
NAGE Niagen Bioscience	$99.60M	7.15	$0.06 per share	158.07	$0.60 per share	15.07
VIR Vir Biotechnology	$74.21M	9.37	N/A	N/A	$8.35 per share	0.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EPRX Eupraxia Pharmaceuticals	-$25.50M	-$0.76	N/A	N/A	N/A	N/A	-367.73%	-112.23%	8/6/2025 (Estimated)
GHRS GH Research	-$38.96M	-$0.79	N/A	N/A	N/A	N/A	-19.20%	-18.40%	9/2/2025 (Estimated)
NAGE Niagen Bioscience	$8.55M	$0.17	53.18	∞	N/A	13.07%	19.06%	12.20%	N/A
VIR Vir Biotechnology	-$521.96M	-$4.22	N/A	N/A	N/A	-2,769.04%	-47.46%	-39.33%	8/6/2025 (Confirmed)

Latest EPRX, NAGE, GHRS, and VIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	N/A	EPRX Eupraxia Pharmaceuticals	-$0.21	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	VIR Vir Biotechnology	-$0.83	N/A	N/A	N/A	$2.38 million	N/A
5/8/2025	Q1 2025	GHRS GH Research	-$0.61	-$0.19	+$0.42	-$0.19	N/A	N/A
5/7/2025	Q1 2025	VIR Vir Biotechnology	-$0.83	-$0.88	-$0.05	-$0.88	$8.59 million	$3.03 million
5/6/2025	Q1 2025	EPRX Eupraxia Pharmaceuticals	-$0.19	-$0.21	-$0.02	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
NAGE Niagen Bioscience	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EPRX Eupraxia Pharmaceuticals	N/A	11.10	11.10
GHRS GH Research	N/A	29.71	29.71
NAGE Niagen Bioscience	N/A	3.66	3.12
VIR Vir Biotechnology	N/A	6.79	6.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EPRX Eupraxia Pharmaceuticals	N/A
GHRS GH Research	56.90%
NAGE Niagen Bioscience	15.41%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
EPRX Eupraxia Pharmaceuticals	N/A
GHRS GH Research	41.60%
NAGE Niagen Bioscience	9.39%
VIR Vir Biotechnology	16.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EPRX Eupraxia Pharmaceuticals	29	35.96 million	N/A	N/A
GHRS GH Research	10	52.03 million	30.38 million	Optionable
NAGE Niagen Bioscience	120	78.77 million	71.37 million	N/A
VIR Vir Biotechnology	580	138.24 million	116.12 million	Optionable

EPRX, NAGE, GHRS, and VIR Headlines

Recent News About These Companies

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Rating of "Moderate Buy" from Brokerages

August 1 at 3:10 AM | marketbeat.com

Vir Biotechnology Pivots to Cancer, Infectious Disease after Commercial and Clinical Setbacks

July 31 at 7:23 PM | genengnews.comG

Vir Biotechnology (VIR) Projected to Post Quarterly Earnings on Wednesday

July 31 at 9:31 AM | marketbeat.com

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

July 31 at 8:05 AM | businesswire.com

Allianz Asset Management GmbH Has $2 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

July 31 at 4:40 AM | marketbeat.com

Victory Capital Management Inc. Has $1.12 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)

July 31 at 4:33 AM | marketbeat.com

Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

July 30 at 11:07 AM | zacks.com

Vir Biotech begins patient dosing in phase 1 trial of EGFR-targeting PRO-XTEN dual-masked T-cell engager VIR-5525 to treat solid tumours

July 26, 2025 | pharmabiz.comP

First subject dosed in Phase I trial of Vir Biotechnology’s VIR-5525

July 25, 2025 | finance.yahoo.com

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

July 24, 2025 | businesswire.com

Vir Biotechnology: Hep B And Cancer Projects March On

July 23, 2025 | seekingalpha.com

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

July 22, 2025 | businesswire.com

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $19,615.42 in Stock

July 18, 2025 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $37,174.12 in Stock

July 18, 2025 | marketbeat.com

Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells 3,586 Shares of Stock

July 18, 2025 | insidertrades.com

Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board

July 14, 2025 | finance.yahoo.com

Raymond James Initiates Coverage of Vir Biotechnology (VIR) with Outperform Recommendation

July 12, 2025 | msn.com

Vir Biotechnology (NASDAQ:VIR) Now Covered by Analysts at Raymond James Financial

July 11, 2025 | marketbeat.com

Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock?

July 10, 2025 | zacks.com

Vir Biotechnology (NASDAQ:VIR) Trading Up 9.2% - What's Next?

July 9, 2025 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Recommendation of "Moderate Buy" from Analysts

July 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Tesla: 2 Plays Ahead of Next Week's Earnings Report
By Sam Quirke | July 15, 2025
View Tesla: 2 Plays Ahead of Next Week's Earnings Report
This Fund Manager Says You Should Get Out of Tesla and Apple—Now
By Brian O'Connell | July 16, 2025
View This Fund Manager Says You Should Get Out of Tesla and Apple—Now
These 2 Tech Stocks With 50%+ ROIC Are Built to Beat the Market
By Leo Miller | July 24, 2025
View These 2 Tech Stocks With 50%+ ROIC Are Built to Beat the Market
Full Steam Ahead: The Bullish Case for Carnival Stock
By Jeffrey Neal Johnson | July 18, 2025
View Full Steam Ahead: The Bullish Case for Carnival Stock
Iron Mountain Down 23% From Its 1-Year High—Is It Undervalued?
By Jordan Chussler | July 21, 2025
View Iron Mountain Down 23% From Its 1-Year High—Is It Undervalued?

EPRX, NAGE, GHRS, and VIR Company Descriptions

Eupraxia Pharmaceuticals NASDAQ:EPRX

$5.30 -0.10 (-1.78%)

Closing price 08/1/2025 03:50 PM Eastern

Extended Trading

$5.58 +0.27 (+5.18%)

As of 08/1/2025 05:16 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

GH Research NASDAQ:GHRS

$13.74 -0.62 (-4.32%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$13.72 -0.03 (-0.18%)

As of 08/1/2025 06:38 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Niagen Bioscience NASDAQ:NAGE

$9.04 -0.31 (-3.32%)

As of 08/1/2025 04:00 PM Eastern

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Vir Biotechnology NASDAQ:VIR

$5.03 -0.04 (-0.79%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$5.17 +0.14 (+2.86%)

As of 08/1/2025 04:16 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time